Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

  • David R. Lally*
  • , Anat Loewenstein
  • , Jennifer J. Arnold
  • , Yit C. Yang
  • , Kinfemichael Gedif
  • , Catherine Best
  • , Hersh Patel
  • , Ramin Tadayoni
  • , Jeffrey S. Heier
    • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Neuroscience